Annual EBITDA
-$80.10 M
-$20.19 M-33.70%
December 31, 2023
Summary
- As of February 12, 2025, TCRX annual EBITDA is -$80.10 million, with the most recent change of -$20.19 million (-33.70%) on December 31, 2023.
- During the last 3 years, TCRX annual EBITDA has fallen by -$55.09 million (-220.35%).
- TCRX annual EBITDA is now -485.04% below its all-time high of -$13.69 million, reached on December 31, 2019.
Performance
TCRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$27.90 M
+$1.69 M+5.71%
September 30, 2024
Summary
- As of February 12, 2025, TCRX quarterly EBITDA is -$27.90 million, with the most recent change of +$1.69 million (+5.71%) on September 30, 2024.
- Over the past year, TCRX quarterly EBITDA has dropped by -$7.17 million (-34.60%).
- TCRX quarterly EBITDA is now -421.53% below its all-time high of -$5.35 million, reached on June 30, 2020.
Performance
TCRX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$102.91 M
-$7.17 M-7.49%
September 30, 2024
Summary
- As of February 12, 2025, TCRX TTM EBITDA is -$102.91 million, with the most recent change of -$7.17 million (-7.49%) on September 30, 2024.
- Over the past year, TCRX TTM EBITDA has dropped by -$24.02 million (-30.46%).
- TCRX TTM EBITDA is now -1800.72% below its all-time high of -$5.41 million, reached on March 31, 2020.
Performance
TCRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TCRX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -33.7% | -34.6% | -30.5% |
| 3 y3 years | -220.3% | -34.6% | -30.5% |
| 5 y5 years | -485.0% | -34.6% | -30.5% |
TCRX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -76.8% | at low | -113.7% | +5.7% | -127.1% | at low |
| 5 y | 5-year | -485.0% | at low | -421.5% | +5.7% | -1800.7% | at low |
| alltime | all time | -485.0% | at low | -421.5% | +5.7% | -1800.7% | at low |
TScan Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$27.90 M(-5.7%) | -$102.91 M(+7.5%) |
| Jun 2024 | - | -$29.59 M(+6.0%) | -$95.73 M(+8.9%) |
| Mar 2024 | - | -$27.93 M(+59.8%) | -$87.92 M(+9.8%) |
| Dec 2023 | -$80.10 M(+33.7%) | -$17.48 M(-15.7%) | -$80.10 M(+1.5%) |
| Sep 2023 | - | -$20.73 M(-4.8%) | -$78.88 M(+8.1%) |
| Jun 2023 | - | -$21.78 M(+8.3%) | -$72.94 M(+12.1%) |
| Mar 2023 | - | -$20.11 M(+23.6%) | -$65.06 M(+8.6%) |
| Dec 2022 | -$59.91 M | -$16.26 M(+9.9%) | -$59.91 M(+5.7%) |
| Sep 2022 | - | -$14.79 M(+6.5%) | -$56.70 M(+0.0%) |
| Jun 2022 | - | -$13.89 M(-7.2%) | -$56.69 M(+7.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$14.96 M(+14.6%) | -$52.82 M(+16.6%) |
| Dec 2021 | -$45.30 M(+81.2%) | -$13.06 M(-11.7%) | -$45.31 M(+14.2%) |
| Sep 2021 | - | -$14.78 M(+47.6%) | -$39.66 M(+25.1%) |
| Jun 2021 | - | -$10.02 M(+34.5%) | -$31.71 M(+17.3%) |
| Mar 2021 | - | -$7.45 M(+0.5%) | -$27.04 M(+8.1%) |
| Dec 2020 | -$25.00 M(+82.6%) | - | - |
| Dec 2020 | - | -$7.41 M(+8.6%) | -$25.00 M(+42.2%) |
| Sep 2020 | - | -$6.83 M(+27.6%) | -$17.59 M(+63.4%) |
| Jun 2020 | - | -$5.35 M(-1.2%) | -$10.76 M(+98.8%) |
| Mar 2020 | - | -$5.41 M | -$5.41 M |
| Dec 2019 | -$13.69 M | - | - |
FAQ
- What is TScan Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for TScan Therapeutics?
- What is TScan Therapeutics annual EBITDA year-on-year change?
- What is TScan Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for TScan Therapeutics?
- What is TScan Therapeutics quarterly EBITDA year-on-year change?
- What is TScan Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for TScan Therapeutics?
- What is TScan Therapeutics TTM EBITDA year-on-year change?
What is TScan Therapeutics annual EBITDA?
The current annual EBITDA of TCRX is -$80.10 M
What is the all time high annual EBITDA for TScan Therapeutics?
TScan Therapeutics all-time high annual EBITDA is -$13.69 M
What is TScan Therapeutics annual EBITDA year-on-year change?
Over the past year, TCRX annual EBITDA has changed by -$20.19 M (-33.70%)
What is TScan Therapeutics quarterly EBITDA?
The current quarterly EBITDA of TCRX is -$27.90 M
What is the all time high quarterly EBITDA for TScan Therapeutics?
TScan Therapeutics all-time high quarterly EBITDA is -$5.35 M
What is TScan Therapeutics quarterly EBITDA year-on-year change?
Over the past year, TCRX quarterly EBITDA has changed by -$7.17 M (-34.60%)
What is TScan Therapeutics TTM EBITDA?
The current TTM EBITDA of TCRX is -$102.91 M
What is the all time high TTM EBITDA for TScan Therapeutics?
TScan Therapeutics all-time high TTM EBITDA is -$5.41 M
What is TScan Therapeutics TTM EBITDA year-on-year change?
Over the past year, TCRX TTM EBITDA has changed by -$24.02 M (-30.46%)